The prevalence of malignant neoplastic and non-malignant gastrointestinal lesions in cardiology inpatients

Journal of Cardiology

Volumn 61, Issue 2, 2013, Pages 181-185

  Sakamoto, Aiko ^a   Fujishiro, Mitsuhiro ^a   Koike, Kazuhiko ^a   Nagai, Ryozo ^a   Ishizaka, Nobukazu ^a,b  

^a UNIVERSITY OF TOKYO   (Japan)

^b OSAKA MEDICAL COLLEGE   (Japan)

Author keywords

Anticoagulants; Antiplatelet therapy; Cardiovascular disease; Endoscopic screening; Malignancy

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; BERAPROST; CILOSTAZOL; CLOPIDOGREL; DIPYRIDAMOLE; ETHYL ICOSAPENTATE; LIMAPROST; SARPOGRELATE; TICLOPIDINE; TRAPIDIL; UNCLASSIFIED DRUG; WARFARIN;

AGED; ARTICLE; CARDIOLOGY; COLON ULCER; COLORECTAL ADENOMA; COLORECTAL CANCER; COLORECTAL POLYP; DIGESTIVE SYSTEM CANCER; DIGESTIVE SYSTEM INJURY; DISEASE ASSOCIATION; DUODENUM POLYP; ESOPHAGUS CANCER; ESOPHAGUS POLYP; ESOPHAGUS ULCER; FEMALE; GASTROINTESTINAL ENDOSCOPY; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; OCCULT BLOOD; PREDICTION; RETROSPECTIVE STUDY; STOMACH ADENOMA; STOMACH CANCER; STOMACH POLYP; STOMACH ULCER;

ADENOMA; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ENDOSCOPY, GASTROINTESTINAL; FEMALE; GASTROINTESTINAL DISEASES; GASTROINTESTINAL NEOPLASMS; HEART DISEASES; HUMANS; MALE; OCCULT BLOOD; PLATELET AGGREGATION INHIBITORS; POLYPS; PREVALENCE; RETROSPECTIVE STUDIES; RISK FACTORS; TOKYO; ULCER;

EID: 84873098968     PISSN: 09145087     EISSN: 18764738     Source Type: Journal    
DOI: 10.1016/j.jjcc.2012.10.002     Document Type: Article

References (35)

1. Manoukian S.V., Feit F., Mehran R., Voeltz M.D., Ebrahimi R., Hamon M., Dangas G.D., Lincoff A.M., White H.D., Moses J.W., King S.B., Ohman E.M., Stone G.W. Impact of major bleeding on 30-day mortality and clinical outcomes in patients with acute coronary syndromes: an analysis from the ACUITY Trial. J Am Coll Cardiol 2007, 49:1362-1368.
2. van Es R.F., Jonker J.J., Verheugt F.W., Deckers J.W., Grobbee D.E. Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): a randomised controlled trial. Lancet 2002, 360:109-113.
3. Feit F., Voeltz M.D., Attubato M.J., Lincoff A.M., Chew D.P., Bittl J.A., Topol E.J., Manoukian S.V. Predictors and impact of major hemorrhage on mortality following percutaneous coronary intervention from the REPLACE-2 trial. Am J Cardiol 2007, 100:1364-1369.
4. Manzano-Fernandez S., Pastor F.J., Marin F., Cambronero F., Caro C., Pascual-Figal D.A., Garrido I.P., Pinar E., Valdes M., Lip G.Y. Increased major bleeding complications related to triple antithrombotic therapy usage in patients with atrial fibrillation undergoing percutaneous coronary artery stenting. Chest 2008, 134:559-567.
5. Yamashita T. Frontiers of anticoagulation therapy for atrial fibrillation. J Cardiol 2011, 58:1-5.
6. Yusuf S., Zhao F., Mehta S.R., Chrolavicius S., Tognoni G., Fox K.K. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001, 345:494-502.
7. Serebruany V.L., Malinin A.I., Ferguson J.J., Vahabi J., Atar D., Hennekens C.H. Bleeding risks of combination vs. single antiplatelet therapy: a meta-analysis of 18 randomized trials comprising 129,314 patients. Fundam Clin Pharmacol 2008, 22:315-321.
8. Park K.H., Jeong M.H., Lee M.G., Ko J.S., Sim D.S., Yoon N.S., Yoon H.J., Hong Y.J., Kim K.H., Park H.W., Kim J.H., Ahn Y., Cho J.G., Park J.C., Kang J.C. What is the optimal duration of triple anti-platelet therapy in patients with acute myocardial infarction undergoing drug-eluting stent implantation?. J Cardiol 2011, 57:53-60.
9. Nakagawa T., Hiasa Y., Hosokawa S., Minami T., Yano Y., Yoneda K., Mizobe M., Murakami N., Tobetto Y., Chen H., Miyazaki S., Mahara K., Ogura R., Miyajima H., Yuba K., et al. The potential benefits and risks of the use of dual antiplatelet therapy beyond 6 months following sirolimus-eluting stent implantation for low-risk patients. J Cardiol 2011, 57:283-289.
10. Carey R.J. Warfarin-induced rectal bleeding as clue to colon cancer. Lancet 1984, 1:505-506.
11. Markle H.V. Coronary artery disease associated with Helicobacter pylori infection is at least partially due to inadequate folate status. Med Hypotheses 1997, 49:289-292.
12. Tenenbaum A., Boyko V., Fisman E.Z., Goldenberg I., Adler Y., Feinberg M.S., Motro M., Tanne D., Shemesh J., Schwammenthal E., Behar S. Does the lipid-lowering peroxisome proliferator-activated receptors ligand bezafibrate prevent colon cancer in patients with coronary artery disease?. Cardiovasc Diabetol 2008, 7:18.
13. Bruce W.R., Wolever T.M., Giacca A. Mechanisms linking diet and colorectal cancer: the possible role of insulin resistance. Nutr Cancer 2000, 37:19-26.
14. Heeringa J., Kors J.A., Hofman A., van Rooij F.J., Witteman J.C. Cigarette smoking and risk of atrial fibrillation: the Rotterdam Study. Am Heart J 2008, 156:1163-1169.
15. Muller A.D., Sonnenberg A., Wasserman I.H. Diseases preceding colon cancer. A case-control study among veterans. Dig Dis Sci 1994, 39:2480-2484.
16. Chan A.O., Jim M.H., Lam K.F., Morris J.S., Siu D.C., Tong T., Ng F.H., Wong S.Y., Hui W.M., Chan C.K., Lai K.C., Cheung T.K., Chan P., Wong G., Yuen M.F., et al. Prevalence of colorectal neoplasm among patients with newly diagnosed coronary artery disease. JAMA 2007, 298:1412-1419.
17. Ishizaka N., Sakamoto A., Fujishiro M., Nagai R., Koike K. Gastrointestinal malignancies and cardiovascular diseases-non-negligible comorbidity in an era of multi-antithrombotic drug use. J Cardiol 2011, 58:199-207.
18. Guzzetti S., Costantino G., Vernocchi A., Sada S., Fundaro C. First diagnosis of colorectal or breast cancer and prevalence of atrial fibrillation. Intern Emerg Med 2008, 3:227-231.
19. Pons F., Lupon J., Urrutia A., Gonzalez B., Crespo E., Diez C., Cano L., Cabanes R., Altimir S., Coll R., Pascual T., Valle V. Mortality and cause of death in patients with heart failure: findings at a specialist multidisciplinary heart failure unit. Rev Esp Cardiol 2010, 63:303-314.
20. Yamamoto K., Miyata T., Nagawa H. The high prevalence of colorectal neoplasms in preoperative patients with abdominal aortic aneurysm or peripheral artery disease. Eur J Vasc Endovasc Surg 2007, 33:397-400.
21. Koracevic G.P. Cancer is an insufficiently recognized risk factor for atrial fibrillation. J Emerg Med 2012, 42:312-313.
22. Martin R., Delgado J.M., Molto J.M., Vicent J.M., Manzanares R., Insa R., Matias-Guiu J. Cardiovascular reflexes in patients with malignant disease. Ital J Neurol Sci 1992, 13:125-129.
23. Dunlay S.M., Redfield M.M., Weston S.A., Therneau T.M., Hall Long K., Shah N.D., Roger V.L. Hospitalizations after heart failure diagnosis a community perspective. J Am Coll Cardiol 2009, 54:1695-1702.
24. Yang S.Y., Kim Y.S., Chung S.J., Song J.H., Choi S.Y., Park M.J., Yim J.Y., Lim S.H., Kim D., Kim C.H., Kim J.S., Song I.S. Association between colorectal adenoma and coronary atherosclerosis detected by CT coronary angiography in Korean men; a cross-sectional study. J Gastroenterol Hepatol 2010, 25:1795-1799.
25. Chan A.T., Ogino S., Fuchs C.S. Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N Engl J Med 2007, 356:2131-2142.
26. Rothwell P.M., Fowkes F.G., Belch J.F., Ogawa H., Warlow C.P., Meade T.W. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet 2011, 377:31-41.
27. Eberhart C.E., Coffey R.J., Radhika A., Giardiello F.M., Ferrenbach S., DuBois R.N. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994, 107:1183-1188.
28. Elwood P.C., Gallagher A.M., Duthie G.G., Mur L.A., Morgan G. Aspirin, salicylates, and cancer. Lancet 2009, 373:1301-1309.
29. Eikelboom J.W., Mehta S.R., Anand S.S., Xie C., Fox K.A., Yusuf S. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation 2006, 114:774-782.
30. Yang X., Alexander K.P., Chen A.Y., Roe M.T., Brindis R.G., Rao S.V., Gibler W.B., Ohman E.M., Peterson E.D. The implications of blood transfusions for patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE National Quality Improvement Initiative. J Am Coll Cardiol 2005, 46:1490-1495.
31. Fox K.A., Mehta S.R., Peters R., Zhao F., Lakkis N., Gersh B.J., Yusuf S. Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the clopidogrel in unstable angina to prevent recurrent ischemic events (CURE) trial. Circulation 2004, 110:1202-1208.
32. Iles-Shih L., Collins J.F., Holub J.L., Lieberman D.A. Prevalence of significant neoplasia in FOBT-positive patients on warfarin compared with those not on warfarin. Am J Gastroenterol 2010, 105:2030-2034.
33. Kershenbaum A., Lavi I., Rennert G., Almog R. Fecal occult blood test performance indicators in warfarin-treated patients. Dis Colon Rectum 2010, 53:224-229.
34. Akl E.A., Vasireddi S.R., Gunukula S., Yosuico V.E.D., Barba M., Terrenato I., Sperati F., Schünemann H. Oral anticoagulation in patients with cancer who have no therapeutic or prophylactic indication for anticoagulation. Cochrane Database Syst Rev 2011, (6). Art. No.: CD006466. 10.1002/14651858.CD006466.pub3.
35. Aida K., Yoshikawa H., Mochizuki C., Mori A., Muto S., Fukuda T., Otsuki M. Clinicopathological features of gastric cancer detected by endoscopy as part of annual health checkup. J Gastroenterol Hepatol 2008, 23:632-637.